David A. Spellman is CFO & VP +1 at Akebia Therapeutics, Inc. (AKBA). They have made 5 open-market trades across 1 company since 2021, most recently 2023-05-16.
CIK 0001733204
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKBA | 446,483 | $308K |
Shares reported on the most recent Form 4, priced at the 2023-05-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKBA | SELL | 2023-05-16 | 2023-05-18 | $1.07 | $136K | -3.7% | +4.6% | +16.7% |
| AKBA | SELL | 2023-03-01 | 2023-03-03 | $0.88 | $6K | -30.0% | -39.8% | +13.6% |
| AKBA | SELL | 2023-02-27 | 2023-03-01 | $0.81 | $6K | -12.2% | -34.8% | +11.5% |
| AKBA | SELL | 2022-02-28 | 2022-03-02 | $2.15 | $18K | -3.2% | -73.0% | -85.0% |
| AKBA | SELL | 2021-04-01 | 2021-04-01 | $3.40 | $3K | -7.3% | -5.4% | +12.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.